OIS Podcast | Ophthalmology's leading Podcast

The last time we connected with Sean Ianchulev, MD, MPH , he shared Transcend's ultimately winning story. Now, he's the CEO and CMO of Eyenovia, a four-year-old company that's developing a line of therapeutics for Glaucoma, Dry Eye, Mydriasis, and Myopia. The company says its high-precision microdosing can deliver smaller doses with greater effect by uniformly coating the corneal su...

Hear the latest from OIS events as the OIS Podcast connects with Tom Frinzi and Joseph Boorady , the new leadership at Johnson & Johnson Vision. Next, CEO Jeffrey Nau introduces Oyster Point to OIS while Rob Thornhill , CEO of Tear Film Innovations, explains his company's treatment for Meibomian Gland Disorder.

Nicox has had quite a year, bringing two new ophthalmology projects to the market through partnerships with Bausch + Lomb and Eyevance Pharmaceuticals . So what's next for the global company? CEO Michele Garufi provides answers. James V. Mazzo, global president for Carl Zeiss Meditec's Strategic Business Unit Ophthalmic Devices, sits down with us at OIS@ASCRS to talk about his three year...

The OIS Podcast returns with a double feature. Avedro CEO Reza Zadno talks about the company's latest $25 million round. Also, Bill Meury, CCO of Allergan, visits at OIS@ASCRS to talk about the company's appetite for acquiring innovation. You can watch our April 12 interview with Dr. Zadno at OIS@ASCRS here. You can also watch the podcast interview with Bill Meury, which was conducted at...

Whitney Hauser, OD, has built a very visible brand as the Dry Eye Coach. With a website, podcasts, and sizable following on social media, she is building a platform that can help promote new treatments and fellow eye care providers. In this podcast, Dr. Hauser discusses new technology that can help treat patients. But she also shares how social media can help build and maintain a practice.

Al Waterhouse , President and COO of AcuFocus, tells the OIS Podcast why the company opted to sell its former flagship product to focus on IOLs. In this discussion, he discusses some of the headwinds in the corneal inlay market. Waterhouse also shares a few details on structure of the sale, which makes AcuFocus in interested partner in Kamra's future success.

SightLife Surgical in 2016 spun out of the well-known SightLife eye bank, capitalized by Flying L Partners. Two years later, Monty Montoya , president and CEO, explains what the start-up is doing to build a new market in cornea products. In this podcast, Montoya discusses the Kamra acquisition and hints at news he'll be releasing at OIS@ASCRS .

The last time OIS Podcast talked with David Muller, he was leaving Avedro to start a new company. Two years later, Allotex has raised capital from a strategic investor and is preparing to enter clinical trials in Europe.

Sue Washer , AGTC president and CEO, has joined the board of directors of the Biotechnology Innovation Organization (BIO). In this podcast, she talks about how she'll fulfill her duties for the biotech advocacy organization.

Robert Dempsey , head of Shire's global ophthalmics franchise, will be a headliner at next week's OIS Launch Dry Eye Innovation Dinner held during the SECO 2018 meeting. In this podcast, Dempsey discusses the importance optometrists are playing in Shire's strategy

OIS - the Ophthalmology Innovation Summit - is introducing a new OIS Launch program to raise awareness and inform early adopters on recently launched and soon to be approved therapies. The inaugural OIS Launch is an invitation-only dinner program led by Paul Karpecki, OD , Joe Boorady, OD , and Emmett Cunningham, MD , who have developed a program to feature select companies with emerging dry eye t...

New CEO Antony Mattessich says Ocular Therapeutix has learned its mistakes after receiving two CRLs from the FDA. With new leadership and a clear vision, the company is ready to push forward as a full-fledged biopharmaceutical company.

A veteran of bioelectronic medicine, Khalid Ishaque joined Pixium Vision four years ago after recognizing the promise of using implantable devices to restore vision. Today, the company is developing not one - but two - technologies that could help restore sight.

Apple made headlines with a promise to spend repatriated dollars on R&D in the US. In this week’s podcast we talk with three Wall Street analysts to understand what we can expect to see from pharma and Medtech companies following the monster acquisitions of Juno, Kite et al. What ophthalmology companies might be acquisition targets? Will Medtech companies follow suit?

Cedric Francois, president and CEO, discusses his debut performance at JP Morgan in which he laid out the company’s plans for a Phase III trial of APL-2, the promising treatment for geographic atrophy. Francois shared the details of the trial, talked about going public, and shared one of the least recognized – but most important – challenges facing biopharma companies.

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.

Oyster Point Pharma CEO Jeff Nau sheds some light on the new dry eye start-up, which is tapping much of the leadership and investment team that made Oculeve successful. He also talks about his own experiences leading high-profile clinical programs at Ophthotech and Genentech. What lessons will he bring into his new CEO role?

Michael Abramoff, MD, PhD, president, director, and co-founder of IDx, tells how the start-up is using artificial intelligence to better diagnose diabetic retinopathy. The company hopes to get FDA approval of its IDx-DR system.

In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, PhD, MPH , delivers a 360-degree review of ophthalmology’s more promising pipelines. To download a copy of an extended version of the Year in Review report delivered at OIS@AAO click here .

In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, delivers a 360-degree review of ophthalmology’s more promising pipelines.

In interviews at OIS@AAO, we talk with Robert Dempsey, global head of Shire’s ophthalmic business, about the international launch of Xiidra. Joseph Boorady, CEO and president of TearScience, lays out the company’s plans since being acquired by Johnson & Johnson Vision. Finally, Tom Gadek, president and CEO of TearSolutions, explains how he’s hoping to score another winning dry eye treatment wi...

Brent Saunders, president, CEO, and chairman of global leader Allergan, sits down at OIS@AAO to discuss what impact the pending loss of the Restasis patent could have on the company. He also rejects talk of Allergan breaking off its ophthalmology business, saying the company is in the sector to stay.

Eric Donnenfeld, MD, founding partner of Ophthalmology Consultants of Long Island, explains how his practice will use a capital infusion from growth equity firm Blue Sea Capital. Dr. Donnenfeld also opines on the growing cooperation - and competition - between ophthalmologists and optometrists. Plus, he explains how he uses CheckedUp to engage his patients.

OIS co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, talks about OIS’ evolution over nearly a decade of meetings. The addition of Breakfast Breakout Sessions and Master Classes has opened opportunities for speakers and attendees. Dr. Cunningham, a partner at Clarus, also walks us through the agenda of next week’s OIS@AAO in New Orleans. This year’s agenda includes several new topics and formats as...

Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update on the late-stage trials of Roclatan.